Clinical significance and prevalence of T315I mutation in Imatinib Mesylate resistance in Indian Chronic Myeloid Leukemia patients. (First study from India)

被引：0
|
作者：
Mir, Rashid [1 ]
Sazawal, S. [1 ]
Chobey, R. [1 ]
Bohra, B. [1 ]
Bharti, S. [1 ]
Ravi, K. [1 ]
Pravas, M. [1 ]
Mehraj, Q. [2 ]
Yasrib, M. [2 ]
Mudasir, T. [2 ]
Shyam, R. [1 ]
Saxena, R. [1 ]
机构：
[1] All India Inst Med Sci, Dept Haematol, New Delhi, India
[2] Univ Kashmir, Srinagar 190006, Jammu & Kashmir, India
来源：
JOURNAL OF MEDICAL GENETICS | 2008年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [31] Stabilization of MYC G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation
    Sun, Yuening
    Chen, Xin
    Liao, Siyan
    Liu, Aochu
    Zhou, Huan
    Jiang, Liling
    Ding, Wa
    Mei, Wenjie
    Liu, Jinbao
    Shi, Xianping
    GENES & DISEASES, 2023, 10 (02) : 399 - 402
  • [32] Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation
    Nicolini, Franck E.
    Mauro, Michael J.
    Martinelli, Giovanni
    Kim, Dong-Wook
    Soverini, Simona
    Mueller, Martin C.
    Hochhaus, Andreas
    Cortes, Jorge
    Chuah, Charles
    Dufva, Inge H.
    Apperley, Jane F.
    Yagasaki, Fumiharu
    Pearson, Jay D.
    Peter, Senaka
    Rodriguez, Cesar Sanz
    Preudhomme, Claude
    Giles, Francis
    Goldman, John M.
    Zhou, Wei
    BLOOD, 2009, 114 (26) : 5271 - 5278
  • [33] Clinical characteristics and outcome of patients (pts) with T315I mutation after imatinib failure.
    Jabbour, Elias
    Kantarjian, Hagop
    Jones, Dan
    Giles, Francis
    Borthakur, Gautam
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2006, 108 (11) : 621A - 621A
  • [34] Imatinib mesylate as first line therapy in patients with Chronic Myeloid Leukemia (CML) - An experience from eastern India
    Dey, S.
    Mukhopadhyay, S.
    Gorai, K.
    Paul, C.
    Gupta, P.
    Choudhury, R.
    Ahmed, R.
    Mukhopadhyay, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 51 - 52
  • [35] I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition
    Gao, Congying
    Zhang, Lei
    Xu, Yun
    Ma, Xiangyu
    Chen, Peilei
    Chen, Zhe-Sheng
    Wei, Liuya
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [36] HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation
    Kim, Soo Jung
    Jung, Kyung Hee
    Yan, Hong Hua
    Son, Mi Kwon
    Fang, Zhenghuan
    Ryu, Ye-Lim
    Lee, Hyunseung
    Lim, Joo Han
    Suh, Jun-Kyu
    Kim, JinHee
    Lee, Soyoung
    Hong, Sungwoo
    Hong, Soon-Sun
    ONCOTARGET, 2015, 6 (03) : 1507 - 1518
  • [37] Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation
    Combes, Francois Pierre
    Sy, Sherwin K. B.
    Li, Ying Fei
    Lorenzo, Sebastien
    Dasgupta, Kohinoor
    Kapoor, Shruti
    Hoch, Matthias
    Ho, Yu-Yun
    CLINICAL PHARMACOKINETICS, 2024, 63 (09) : 1301 - 1312
  • [38] HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway
    Le Yin
    Qingyang Zhang
    Sisi Xie
    Zhao Cheng
    Ruijuan Li
    Hongkai Zhu
    Qian Yu
    Huan Yuan
    Canfei Wang
    Hongling Peng
    Guangsen Zhang
    Human Cell, 2023, 36 : 1564 - 1577
  • [39] Tyrosine kinase inhibitor treatment outcome in a single center cohort of chronic myeloid leukemia patients. The role of the T315I ABL kinase domain mutation
    Dima, Delia
    Trifa, Adrian P.
    Patiu, Mariana
    Vesa, Cristian S.
    Frinc, Ioana C.
    Petrov, Ljubomir
    Cucuianu, Andrei
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2013, 21 (01): : 29 - 37
  • [40] Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial
    Cortes, J. E.
    Khoury, H. J.
    Corm, S.
    Nicolini, F.
    Schenk, T.
    Jones, D.
    Hochhaus, A.
    Craig, A. R.
    Humphriss, E.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345